Stephanie Clare Blake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stephanie Clare Blake has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Silas Daniel
Department of Dermatology Royal Children's Hospital Melbourne Parkville Victoria Australia
2 shared publications - Dedee Frances Murrell
Department of Dermatology, St George Hospital, Sydney, Australia
2 shared publications - Alexa Seal
School of Medicine (Rural Clinical School), the University of Notre Dame Australia Wagga Wagga New South Wales Australia
1 shared publication - Anne E. Cust
The Daffodil Centre, The University of Sydney, and Cancer Council NSW, Sydney, Australia
1 shared publication - Bruce K. Armstrong
School of Public Health, University of Sydney, Sydney, Australia
1 shared publication - Caroline G. Watts
Kirby Institute, UNSW Sydney, Sydney, Australia
1 shared publication
Latest Publications
- Open Access
- 24 June 2023
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 64 (3) , 425-429
The association of dermatologist demographic density with melanoma survival in New South Wales, Australia
- 24 June 2023
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 64 (3) , 425-429
Open AccessThe association of dermatologist demographic density with melanoma survival in New South Wales, Australia
- Open Access
- 15 June 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , 427-428
Impact of COVID‐19 on inpatient dermatology consults in an Australian tertiary hospital
- 15 June 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , 427-428
Open AccessImpact of COVID‐19 on inpatient dermatology consults in an Australian tertiary hospital
- Open Access
- 1 December 2019
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 5 (5) , 320-329
Cutaneous lupus erythematosus: A review of the literature
Knowledge with regard to the pathogenesis of lupus erythematosus has progressed rapidly over the past decade, and with it has come promising new agents for the treatment of cutaneous lupus erythematous (CLE). Classification of CLE is performed using clinical features and histopathologic findings, and is crucial for determining prognosis and choosing therapeutic options. Preventative therapy is critical in achieving optimal disease control, and patients should be counseled on sun-safe behavior and smoking cessation. First-line therapy includes topical corticosteroids and calcineurin inhibitors, with antimalarial therapy. Traditionally, refractory disease was treated with oral retinoids, dapsone, and other oral immunosuppressive drugs, but new therapies are emerging with improved side effect profiles and efficacy. Biologic agents, such as belimumab and ustekinumab, have been promising in case studies but will require larger trials to establish their role in routine therapy. Other novel therapies that have been trialed successfully include spleen tyrosine kinase inhibitors and fumaric acid esters. Finally, new evidence has been published recently that describes safer dosing regimens in thalidomide and lenalidomide, both effective medications for CLE. Given the chronic disease course of CLE, long-term treatment-related side effects must be minimized, and the introduction of new steroid-sparing agents is encouraging in this regard.
- 1 December 2019
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 5 (5) , 320-329
Open AccessCutaneous lupus erythematosus: A review of the literature
Knowledge with regard to the pathogenesis of lupus erythematosus has progressed rapidly over the past decade, and with it has come promising new agents for the treatment of cutaneous lupus erythematous (CLE). Classification of CLE is performed using clinical features and histopathologic findings, and is crucial for determining prognosis and choosing therapeutic options. Preventative therapy is critical in achieving optimal disease control, and patients should be counseled on sun-safe behavior and smoking cessation. First-line therapy includes topical corticosteroids and calcineurin inhibitors, with antimalarial therapy. Traditionally, refractory disease was treated with oral retinoids, dapsone, and other oral immunosuppressive drugs, but new therapies are emerging with improved side effect profiles and efficacy. Biologic agents, such as belimumab and ustekinumab, have been promising in case studies but will require larger trials to establish their role in routine therapy. Other novel therapies that have been trialed successfully include spleen tyrosine kinase inhibitors and fumaric acid esters. Finally, new evidence has been published recently that describes safer dosing regimens in thalidomide and lenalidomide, both effective medications for CLE. Given the chronic disease course of CLE, long-term treatment-related side effects must be minimized, and the introduction of new steroid-sparing agents is encouraging in this regard.
- 30 September 2019
- Published by Wiley in Pediatric Dermatology
- Vol. 36 (6) , 843-853
Monitoring trough levels in cyclosporine for atopic dermatitis: A systematic review
Background: Cyclosporine is a useful immunosuppressive agent for achieving disease control in moderate to severe atopic dermatitis in children and adults. However, it carries the potential for nephrotoxicity. Monitoring of drug levels is performed in other patient groups, such as transplant recipients, but is not commonplace in the management of atopic dermatitis.Objectives: To investigate levels of nephrotoxicity associated with cyclosporine use in atopic dermatitis and assess potential correlation with trough levels of cyclosporine.Methods: An electronic search was conducted on MEDLINE, EMBASE, and Cochrane databases for randomized controlled trials and cohort studies assessing the safety profile of cyclosporine compared to placebo or other atopic dermatitis treatments, in adult and pediatric atopic dermatitis patients from 1966 to May 2019. Studies that did not assess renal toxicity were excluded from analysis.Results: Thirty‐eight trials were included for analysis, excluding 11 that did not assess renal toxicity. Descriptive statistical analysis only was performed, due to the high heterogeneity between study methodologies. Significant renal toxicity was seen in 0%‐9% of pediatric participants. Monitoring of trough cyclosporine levels was performed in only 10 of the studies, and their correlation to toxicity or disease activity was not explored.Conclusion: There is limited evidence in atopic dermatitis regarding trough level monitoring of cyclosporine. Currently, the practice is not commonplace, particularly in pediatrics, and this is reflected in trial methodology. Monitoring may be useful in specific pediatric groups, such as those on multiple concurrent medications, patients with hepatic or renal dysfunction and non‐responders to therapy.
- 30 September 2019
- Published by Wiley in Pediatric Dermatology
- Vol. 36 (6) , 843-853
Monitoring trough levels in cyclosporine for atopic dermatitis: A systematic review
Background: Cyclosporine is a useful immunosuppressive agent for achieving disease control in moderate to severe atopic dermatitis in children and adults. However, it carries the potential for nephrotoxicity. Monitoring of drug levels is performed in other patient groups, such as transplant recipients, but is not commonplace in the management of atopic dermatitis.Objectives: To investigate levels of nephrotoxicity associated with cyclosporine use in atopic dermatitis and assess potential correlation with trough levels of cyclosporine.Methods: An electronic search was conducted on MEDLINE, EMBASE, and Cochrane databases for randomized controlled trials and cohort studies assessing the safety profile of cyclosporine compared to placebo or other atopic dermatitis treatments, in adult and pediatric atopic dermatitis patients from 1966 to May 2019. Studies that did not assess renal toxicity were excluded from analysis.Results: Thirty‐eight trials were included for analysis, excluding 11 that did not assess renal toxicity. Descriptive statistical analysis only was performed, due to the high heterogeneity between study methodologies. Significant renal toxicity was seen in 0%‐9% of pediatric participants. Monitoring of trough cyclosporine levels was performed in only 10 of the studies, and their correlation to toxicity or disease activity was not explored.Conclusion: There is limited evidence in atopic dermatitis regarding trough level monitoring of cyclosporine. Currently, the practice is not commonplace, particularly in pediatrics, and this is reflected in trial methodology. Monitoring may be useful in specific pediatric groups, such as those on multiple concurrent medications, patients with hepatic or renal dysfunction and non‐responders to therapy.
- 7 January 2019
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 60 (3) , 251-253
A qualitative discourse analysis of safe sun exposure and vitamin D in Australian print media
- 7 January 2019
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 60 (3) , 251-253
A qualitative discourse analysis of safe sun exposure and vitamin D in Australian print media
- Open Access
- 13 September 2016
- Published by BCS Learning & Development Ltd in Journal of Innovation in Health Informatics
- Vol. 23 (3) , 555-559
Accuracy of Screening Tools for Pap Smears in General Practice
Background Data extraction tools (DETs) are increasingly being used for research and audit of general practice, despite their limitations. Objective This study explores the accuracy of Pap smear rates obtained with a DET compared to that of the Pap smear rate obtained with a manual file audit. Method A widely available DET was used to establish the rate of Pap smears in a large multi-general practice (multi-GP) in regional New South Wales followed by a manual audit of patient files. The main outcome measure was identification of possible discrepancies between the rates established. Results The DET used significantly underestimated the level of cervical screening compared to the manual audit. In some instances, the patient file contained phone/specialist record of Pap smear conducted elsewhere, which accounted for the failure of the DET to detect some smears. Those patients who had Pap smears whose pathology codes differed between time intervals, i.e. from different pathology providers or from within the same provider but using a different code, were less likely to have had their most recent Pap smear detected by the DET (p < 0.001). Conclusion Data obtained from DETs should be used with caution as they may not accurately reflect the rate of Pap smears from electronic medical records. How this fits in DETs are increasingly being used for research and audit of general practice. This study explores the accuracy of Pap smear rates obtained with a DET compared to that of the Pap smear rate obtained with a manual file audit The DET tested significantly underestimated the level of cervical screening compared to manual screening. Data obtained from DETs should be used with caution as they may not accurately reflect the rate of Pap smears from electronic medical records
- 13 September 2016
- Published by BCS Learning & Development Ltd in Journal of Innovation in Health Informatics
- Vol. 23 (3) , 555-559
Open AccessAccuracy of Screening Tools for Pap Smears in General Practice
Background Data extraction tools (DETs) are increasingly being used for research and audit of general practice, despite their limitations. Objective This study explores the accuracy of Pap smear rates obtained with a DET compared to that of the Pap smear rate obtained with a manual file audit. Method A widely available DET was used to establish the rate of Pap smears in a large multi-general practice (multi-GP) in regional New South Wales followed by a manual audit of patient files. The main outcome measure was identification of possible discrepancies between the rates established. Results The DET used significantly underestimated the level of cervical screening compared to the manual audit. In some instances, the patient file contained phone/specialist record of Pap smear conducted elsewhere, which accounted for the failure of the DET to detect some smears. Those patients who had Pap smears whose pathology codes differed between time intervals, i.e. from different pathology providers or from within the same provider but using a different code, were less likely to have had their most recent Pap smear detected by the DET (p < 0.001). Conclusion Data obtained from DETs should be used with caution as they may not accurately reflect the rate of Pap smears from electronic medical records. How this fits in DETs are increasingly being used for research and audit of general practice. This study explores the accuracy of Pap smear rates obtained with a DET compared to that of the Pap smear rate obtained with a manual file audit The DET tested significantly underestimated the level of cervical screening compared to manual screening. Data obtained from DETs should be used with caution as they may not accurately reflect the rate of Pap smears from electronic medical records